{"id":"drug-everolimus","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Stomatitis"},{"rate":"30-40","effect":"Infections"},{"rate":"25-35","effect":"Rash"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"25-35","effect":"Fatigue"},{"rate":"15-25","effect":"Hyperglycemia"},{"rate":"20-30","effect":"Hyperlipidemia"},{"rate":"5-10","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that suppresses cell cycle progression and angiogenesis by blocking the mTORC1 signaling pathway. This leads to reduced tumor cell proliferation and is particularly effective in neuroendocrine tumors where mTOR signaling is often dysregulated. The drug also has immunomodulatory effects that enhance anti-tumor immunity.","oneSentence":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:05.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (pancreatic and non-pancreatic)"},{"name":"Advanced renal cell carcinoma"},{"name":"Breast cancer (hormone receptor positive)"}]},"trialDetails":[{"nctId":"NCT06656364","phase":"NA","title":"Esprit BTK Post-Approval Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-10-21","conditions":"Chronic Limb-Threatening Ischemia","enrollment":200},{"nctId":"NCT07190690","phase":"NA","title":"Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2025-12-19","conditions":"Coronary Artery Disease","enrollment":2100},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":"Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer","enrollment":20},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT07463664","phase":"NA","title":"Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-04-28","conditions":"Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO), Coronary Artery Disease (CAD)","enrollment":200},{"nctId":"NCT06769217","phase":"PHASE4","title":"Clinical Investigation for Everolimus Drug Eluting Stent","status":"COMPLETED","sponsor":"Frisch Medical Device Private Limited","startDate":"2023-01-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":888},{"nctId":"NCT06013007","phase":"NA","title":"Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization","status":"COMPLETED","sponsor":"Zunyi Medical College","startDate":"2023-08-22","conditions":"Acute Coronary Syndrome, De Novo Stenosis","enrollment":161},{"nctId":"NCT07144150","phase":"NA","title":"EVERO Drug-coated Balloon (DCB) Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Cook Research Incorporated","startDate":"2026-02","conditions":"Peripheral Vascular Disease, Peripheral Arterial Disease","enrollment":410},{"nctId":"NCT04895748","phase":"PHASE1","title":"DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-30","conditions":"Carcinoma, Renal Cell","enrollment":40},{"nctId":"NCT07435584","phase":"PHASE1, PHASE2","title":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Colorectal Cancer","enrollment":38},{"nctId":"NCT04390672","phase":"NA","title":"Multivessel TALENT","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-09-22","conditions":"Coronary Artery Disease, Myocardial Ischemia, Coronary Disease","enrollment":1550},{"nctId":"NCT02184416","phase":"","title":"Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-10-31","conditions":"Metastatic Renal Cell Carcinoma (mRCC)","enrollment":554},{"nctId":"NCT05423379","phase":"","title":"XIENCE Skypoint Large Vessel Post Approval Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2022-09-14","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT04893291","phase":"NA","title":"Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM II","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2021-11-16","conditions":"Coronary Artery Disease, Coronary Artery Stenosis","enrollment":1820},{"nctId":"NCT04199026","phase":"NA","title":"Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-02-25","conditions":"Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma","enrollment":20},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT04475380","phase":"","title":"Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents","status":"COMPLETED","sponsor":"Foundation of Cardiovascular Research and Education Enschede","startDate":"2018-09-21","conditions":"Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable","enrollment":1757},{"nctId":"NCT02520063","phase":"PHASE1, PHASE2","title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-02-01","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05476939","phase":"PHASE3","title":"Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-09-29","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered","enrollment":433},{"nctId":"NCT06727305","phase":"PHASE1, PHASE2","title":"MTOR Inhibitors in Older Adults","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02","conditions":"Aging","enrollment":60},{"nctId":"NCT01217931","phase":"PHASE2","title":"Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-19","conditions":"Kidney Cancer","enrollment":180},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT03168776","phase":"NA","title":"PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease","status":"COMPLETED","sponsor":"Sino Medical Sciences Technology Inc.","startDate":"2017-10-13","conditions":"Coronary Artery Disease","enrollment":1629},{"nctId":"NCT07369505","phase":"PHASE1","title":"Sapu003 in Advanced mTOR-sensitive Solid Tumors","status":"RECRUITING","sponsor":"SAPU NANO (US) LLC","startDate":"2025-12-15","conditions":"Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT06214819","phase":"NA","title":"Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2024-03-20","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07002177","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","status":"RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2025-06-01","conditions":"Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":196},{"nctId":"NCT02253108","phase":"NA","title":"The OCT SORT-OUT VIII Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital Skejby","startDate":"2014-05","conditions":"Coronary Artery Disease, Angina Pectoris, Myocardial Infarction","enrollment":160},{"nctId":"NCT05831085","phase":"NA","title":"Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2024-06-14","conditions":"Coronary Artery Stenosis","enrollment":1500},{"nctId":"NCT07270575","phase":"","title":"REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia","status":"NOT_YET_RECRUITING","sponsor":"Cardiovascular and Interventional Radiological Society of Europe","startDate":"2026-04","conditions":"Chronic Limb Threatening Ischemia, Chronic Limb-Threatening Ischemia","enrollment":400},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT07095933","phase":"EARLY_PHASE1","title":"The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-03-01","conditions":"Epilepsy, Drug Resistant","enrollment":5},{"nctId":"NCT02890589","phase":"NA","title":"Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-07","conditions":"Acute Coronary Syndrome","enrollment":22},{"nctId":"NCT07258290","phase":"NA","title":"Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","status":"NOT_YET_RECRUITING","sponsor":"Teleflex","startDate":"2026-05","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":1859},{"nctId":"NCT03284957","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-20","conditions":"Breast Cancer","enrollment":136},{"nctId":"NCT05540223","phase":"NA","title":"Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System","status":"RECRUITING","sponsor":"Biotronik AG","startDate":"2024-05-13","conditions":"Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia","enrollment":1859},{"nctId":"NCT05508906","phase":"PHASE1","title":"Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2022-08-31","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":190},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT05731700","phase":"NA","title":"CVT-ISR First in Human Trial for Coronary In-Stent Restenosis","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2021-10-20","conditions":"In-stent Restenosis","enrollment":51},{"nctId":"NCT05734157","phase":"NA","title":"CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2022-02-17","conditions":"Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion","enrollment":75},{"nctId":"NCT07122167","phase":"NA","title":"Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions","status":"RECRUITING","sponsor":"MDCECRO LLC","startDate":"2025-06-02","conditions":"Peripheral Arterial Disease","enrollment":153},{"nctId":"NCT06271590","phase":"NA","title":"MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels","status":"RECRUITING","sponsor":"Concept Medical Inc.","startDate":"2025-05-20","conditions":"Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases","enrollment":1605},{"nctId":"NCT07165886","phase":"PHASE2, PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":243},{"nctId":"NCT01734512","phase":"PHASE2","title":"PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-12-13","conditions":"Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas","enrollment":65},{"nctId":"NCT06658093","phase":"EARLY_PHASE1","title":"RESTOR: PK/PD mTORi Inhibition in Older Adults","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-08-13","conditions":"Aging","enrollment":194},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT07098195","phase":"NA","title":"To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System","status":"NOT_YET_RECRUITING","sponsor":"Poly Medicure Limited","startDate":"2025-08-18","conditions":"Coronary Artery Disease, Coronary Artery Stenosis, Percutaneous Coronary Intervention","enrollment":2000},{"nctId":"NCT00812786","phase":"PHASE4","title":"Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2007-07","conditions":"Heart Transplant","enrollment":42},{"nctId":"NCT04135807","phase":"EARLY_PHASE1","title":"Implantable Microdevice In Primary Brain Tumors","status":"RECRUITING","sponsor":"Oliver Jonas","startDate":"2020-03-03","conditions":"Grade II Glioma, Grade III Glioma, Grade IV Glioma","enrollment":12},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06972758","phase":"PHASE2","title":"Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-07-01","conditions":"Carcinom, Hepatocellular","enrollment":60},{"nctId":"NCT02246127","phase":"PHASE3","title":"Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2014-10-27","conditions":"Neuroendocrine Tumors","enrollment":141},{"nctId":"NCT05432518","phase":"EARLY_PHASE1","title":"Pilot Trial for Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-06-27","conditions":"Glioblastoma, Recurrent Disease, Recurrent Glioblastoma","enrollment":10},{"nctId":"NCT06942156","phase":"PHASE4","title":"Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2025-08-14","conditions":"Heart Transplant","enrollment":140},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05443087","phase":"NA","title":"TARGETed Therapy Drug MONITOring in DIGestive Oncology","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-08-29","conditions":"Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma","enrollment":330},{"nctId":"NCT01285999","phase":"NA","title":"Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2011-01","conditions":"Atherosclerosis, Coronary Artery Disease","enrollment":500},{"nctId":"NCT06126588","phase":"PHASE2","title":"Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-29","conditions":"Meningioma","enrollment":28},{"nctId":"NCT06718179","phase":"PHASE4","title":"Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":"Acute Coronary Syndrome","enrollment":3150},{"nctId":"NCT02531932","phase":"PHASE2","title":"Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Amy Tiersten","startDate":"2015-12-16","conditions":"Breast Cancer","enrollment":64},{"nctId":"NCT02991807","phase":"PHASE1, PHASE2","title":"RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2017-06-12","conditions":"PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome","enrollment":46},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT04282148","phase":"NA","title":"Abbott Next Generation Drug Eluting Stent 48mm Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2020-06-17","conditions":"Coronary Artery Disease","enrollment":107},{"nctId":"NCT03031470","phase":"PHASE2","title":"Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2015-03-10","conditions":"Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction","enrollment":40},{"nctId":"NCT05544864","phase":"NA","title":"Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5","status":"RECRUITING","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2022-09-28","conditions":"Coronary Artery Disease, Restenoses, Coronary","enrollment":376},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT06692140","phase":"NA","title":"Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":"Ischemia, Myocardial, Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)","enrollment":3150},{"nctId":"NCT06482086","phase":"PHASE2","title":"Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-06-01","conditions":"Locally Advanced Thyroid Gland Carcinoma","enrollment":75},{"nctId":"NCT04862052","phase":"NA","title":"Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis","status":"RECRUITING","sponsor":"Semmelweis University Heart and Vascular Center","startDate":"2021-04-26","conditions":"Coronary Stent Restenosis","enrollment":150},{"nctId":"NCT06682611","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-11-13","conditions":"Unresectable Locally Advanced or Metastatic Solid Tumors","enrollment":380},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT03048825","phase":"PHASE3","title":"Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-02-01","conditions":"ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction","enrollment":7264},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT00811590","phase":"PHASE2","title":"Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-11","conditions":"Peutz-Jeghers Syndrome","enrollment":3},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04185831","phase":"PHASE2","title":"A MolEcularly Guided Anti-Cancer Drug Off-Label Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uppsala University Hospital","startDate":"2020-10-20","conditions":"Solid Tumor","enrollment":167},{"nctId":"NCT06561022","phase":"PHASE2","title":"Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-08-21","conditions":"Breast Cancer","enrollment":260},{"nctId":"NCT05833815","phase":"PHASE2, PHASE3","title":"Addition of Everolimus to Standard of Care in Carcinoma Gallbladder","status":"RECRUITING","sponsor":"Banaras Hindu University","startDate":"2022-11-01","conditions":"Gallbladder Cancer","enrollment":56},{"nctId":"NCT02338609","phase":"PHASE4","title":"Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Growth and Development","enrollment":15},{"nctId":"NCT03154281","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast","status":"COMPLETED","sponsor":"Avera McKennan Hospital & University Health Center","startDate":"2017-07-26","conditions":"Breast Cancer, Ovarian Cancer","enrollment":14},{"nctId":"NCT04893785","phase":"PHASE2","title":"A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2021-06-15","conditions":"Lung Neuroendocrine Neoplasm, GEP Neuroendocrine Tumor","enrollment":35},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT06441539","phase":"NA","title":"Bingo Drug-eluting Balloon Versus a Drug-eluting Stent for Coronary Bifurcation Lesions","status":"NOT_YET_RECRUITING","sponsor":"Yinyi(Liaoning) Biotech Co., Ltd.","startDate":"2024-07-01","conditions":"Coronary Artery Disease","enrollment":218},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03074305","phase":"NA","title":"DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2017-03-08","conditions":"Coronary Artery Disease, Coronary Restenosis","enrollment":""},{"nctId":"NCT06338306","phase":"","title":"Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-01-07","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT02513719","phase":"","title":"XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2013-05-13","conditions":"Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Afinitor"],"phase":"phase_3","status":"active","brandName":"Drug: Everolimus","genericName":"Drug: Everolimus","companyName":"Grupo Espanol de Tumores Neuroendocrinos","companyId":"grupo-espanol-de-tumores-neuroendocrinos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Neuroendocrine tumors (pancreatic and non-pancreatic), Advanced renal cell carcinoma, Breast cancer (hormone receptor positive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}